Related Experiment Video
Updated: Nov 5, 2025
09:44
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
10.3K
Perspectives on metals-based radioimmunotherapy (RIT): moving forward
Jordan M White1,2, Freddy E Escorcia3, Nerissa T Viola2
1Cancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, MI 48201.
Theranostics
|May 17, 2021
Summary
Radioimmunotherapy (RIT) shows promise for solid tumors by targeting cancer cells with radioactive antibodies. Advances in radiometals and antibody platforms offer new strategies to overcome current challenges in RIT development.
Area of Science:
- Oncology
- Radiochemistry
- Immunology
Background:
- Radioimmunotherapy (RIT) is FDA-approved for hematologic cancers but faces challenges in solid tumors.
- RIT utilizes monoclonal antibodies to target tumor-specific antigens and deliver cytotoxic radionuclides.
- Significant advancements have been made in therapeutic radiometals and bifunctional chelators.
Purpose of the Study:
- To review approaches for developing radiometal-based RITs for solid malignancies.
- To discuss the selection of radiometals, chelators, and antibody platforms for RIT.
- To highlight clinical RIT performance, challenges, and future directions.
Main Methods:
- Review of literature on radiometal selection (alpha, beta, Auger electron emitters).
- Discussion of bifunctional chelator development for radiometal-antibody conjugation.
- Analysis of various antibody platforms (full-length, fragments, nanobodies).
Main Results:
- Improved quality and availability of therapeutic radiometals.
- Development of novel bifunctional chelators for effective radiolabeling.
- Diverse antibody formats offer tailored targeting strategies.
Conclusions:
- Radiometal-based RIT holds potential for solid tumor treatment.
- Optimizing radiometal, chelator, and antibody selection is crucial.
- Addressing implementation challenges is key for clinical translation.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
801
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
801
02:57Targeted Cancer Therapies
8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.0K
02:56Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K